The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability to isolate specific cell types from heterogeneous tissue or blood-derived sources such as whole peripheral blood, bone marrow, or cord blood is critical to advancing […]
Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the mobilization and collection procedures are far less invasive for donors with fewer side effects. Another benefit is that significantly more CD34+ cells can be isolated […]
Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by the presence of the cell surface marker CD34, which is useful for their identification and isolation from the bone marrow and peripheral blood. In the […]
Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of this important cell population. Hematopoietic stem cells (HSCs) are an important and rare population of cells that reside in a specialized niche within the bone […]
While next generation cell-based treatments like CAR-T immunotherapies have been the source of much excitement and clinical investment in recent years, cellular therapies have a long, established history in the clinic. Bone marrow (BM) or hematopoietic stem cell transplantation has been the standard of care to treat a variety of blood and immune system diseases […]
